

**Date:** June 20, 2025

To,  
The Manager - Listing Department,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Plot No. C/1, Block-G,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051

**SYMBOL: REMUS**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting of the Company – Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

In compliance with Regulations 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors (“the Board”) of the Company at their Meeting held today i.e. Friday, June 20, 2025 has inter-alia, approved the incorporation of a new subsidiary company under the provisions of the Companies Act, 2013, to undertake the business for providing services related to clinical trials under the name and style of Espee Global Clinical Trial Services Private Limited, or such other name (“Proposed Subsidiary Company”) as may be approved by the Registrar of Companies (“RoC”).

The details as required under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is given in the **Annexure -A.**

Kindly note that the meeting of the Board of Directors of the Company commenced at 11:00 A.M.(IST) and concluded at 11:30 A.M. (IST).

You are requested to take the aforesaid information on your record.

**Thanking you**  
**For, Remus Pharmaceuticals Limited**

---

**Deval Patel**  
Company Secretary and Compliance Officer  
ICSI Membership No.: A60090

## Remus Pharmaceuticals Limited

**REGISTERED OFFICE:** 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,  
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.  
P: 079 2999 9857

E. [remus@remuspharma.com](mailto:remus@remuspharma.com) | W. [www.remuspharma.com](http://www.remuspharma.com)  
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

**Annexure – A**

Disclosures under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with the SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Name: Espee Global Clinical Trial Services Private Limited, or such other name as may be approved by the Registrar of Companies (“RoC”).</p> <p>The Authorized Share Capital will be ₹ 1,00,00,000/- (Rupees One Crore Only) divided into 10,00,000 (Ten Lakhs) equity shares of ₹10/- (Rupees Ten only) each.</p> <p>Turnover: Not Applicable (Company is yet to be incorporated)</p> <p>Date of Incorporation: Not applicable (Company is yet to be incorporated)</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	<p>The Subsidiary once incorporated shall be a related party of the Company.</p> <p>Ms. Roma Vinodbhai Shah and Mrs. Anar Swapnil Shah, Promoters of the Company, are also the promoters of the Proposed Subsidiary Company.</p> <p>Further, the investment in proposed subsidiary company shall be made at arms' length basis.</p>
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>The Proposed Subsidiary Company shall carry on the business of offering clinical trial material management and related services.</p> <p>It will offer solutions for the logistical and operational aspects of managing materials and supplies throughout the lifecycle of a clinical trial.</p> <p>In view of the Company’s strategic objective of expanding its business operations and considering the increase in the demand for reliable and compliant clinical trial service providers in India and globally, it is proposed to incorporate a new subsidiary company.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition	The incorporation of Proposed Subsidiary Company shall be subject to the approval by Ministry of Corporate Affairs.

## Remus Pharmaceuticals Limited

**REGISTERED OFFICE:** 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.  
P: 079 2999 9857

E. [remus@remuspharma.com](mailto:remus@remuspharma.com) | W. [www.remuspharma.com](http://www.remuspharma.com)  
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

6.	Indicative time period for completion of the acquisition	As the Company is yet to be incorporated, therefore, the completion of the same is subject to the completion of the required process of Ministry of Corporate Affairs.
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Subscription to the initial paid-up share capital shall be in cash.
8.	Cost of acquisition or the price at which the shares are acquired	₹ 6,80,000/- (68,000 Equity Shares of Rs.10/- each)
9.	Percentage of shareholding / control acquired and / or number of shares acquired	The Proposed Subsidiary Company is to be incorporated with subscription amount of ₹ 10,00,000/- (Rupees Ten Lakhs) out of which 68% will be subscribed by Remus Pharmaceuticals Limited.
10.	Name of the Holding Company of the incorporated company and relation with listed entity	Listed Company i.e., Remus Pharmaceuticals Limited shall be the Holding Company of the Proposed Subsidiary Company.
11.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Brief Background: The Proposed Subsidiary Company shall be in the business of clinical trial material management and related services.</p> <p>Date of incorporation: Not Applicable (Company is yet to be incorporated)</p> <p>History/Turnover: Not Applicable (Company is yet to be incorporated)</p> <p>Country: India</p>

## Remus Pharmaceuticals Limited

**REGISTERED OFFICE:** 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,  
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.  
P: 079 2999 9857

E. [remus@remuspharma.com](mailto:remus@remuspharma.com) | W. [www.remuspharma.com](http://www.remuspharma.com)  
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536